| Literature DB >> 35410850 |
Hamzah Alzubaidi1, Khadija Hafidh2, Ward Saidawi3, Amna M Othman4, Mahta M Khakpour5, Malaka M Zoghbor6, Eman Abu-Gharbieh7, Karem H Alzoubi8, Jonathan E Shaw9.
Abstract
AIMS: Assess self-care activities, health behaviors, self-efficacy, diabetes distress, challenges, and changes in diabetes treatment and clinical parameters among Arabic-speaking people with T2DM during the COVID-19 pandemic.Entities:
Keywords: COVID-19; Delivery of health care; Diabetes mellitus, type 2; Psychological distress; Self-management; United Arab Emirates
Mesh:
Year: 2022 PMID: 35410850 PMCID: PMC8993045 DOI: 10.1016/j.pcd.2022.03.015
Source DB: PubMed Journal: Prim Care Diabetes ISSN: 1878-0210 Impact factor: 2.567
Sociodemographic and health characteristics of people with type 2 diabetes (N = 206).
| Participant characteristics | n (%) |
|---|---|
| Male sex | 119 (57.8) |
| Age (mean ± SD) | 58.7 ± 11.2 |
| Nationality | |
| Emirati Arabs | 158 (76.7) |
| Non-Emirati Arabs | 48 (23.3) |
| Education Level | |
| Less than high school diploma | 70 (34.6) |
| High school diploma | 66 (32.7) |
| College/Bachelor’s degree | 53 (26.2) |
| Master’s degree | 8 (4.0) |
| Other | 5 (2.5) |
| Employment status | |
| Employed | 78 (37.9) |
| Unemployed | 128 (62.1) |
| Years since diabetes diagnosis (mean ± SD) | 15.7 ± 8.0 |
| Comorbidities | |
| Dyslipidemia | 171 (83.0) |
| High blood pressure | 152 (73.8) |
| History of heart attack | 36 (17.5) |
| Chronic kidney disease | 29 (14.1) |
| Arthritis | 22 (10.7) |
| Others | 151 (73.3) |
| No co-morbidities | 7 (3.5) |
| Diabetes Complications | |
| Neuropathy | 88 (42.7) |
| Retinopathy | 76 (36.9) |
| Albuminuria | 38 (18.4) |
| Amputation | 9 (4.4) |
| Others | 10 (4.9) |
| No complications | 69 (34.0) |
| COVID-19 test result documented | 102 (49.5) |
| Diagnosed with COVID-19 | 13/102 (12.7) |
| Hospitalized due to COVID-19 | 10/13 (76.9) |
Adherence to self-care activities and sleep duration of people with type 2 diabetes during COVID-19 pandemic (N = 206).
| Self-care activities and health behaviors | n (%) | |||||
|---|---|---|---|---|---|---|
| Healthful eating habits | ||||||
| Adherent | 127 (61.7) | |||||
| Non-adherent | 79 (38.3) | |||||
| Fruit and vegetable intake | ||||||
| Adherent | 55 (26.7) | |||||
| Non-adherent | 151 (73.3) | |||||
| Avoiding eating high-fat foods | ||||||
| Adherent | 160 (77.7) | |||||
| Non-adherent | 46 (22.3) | |||||
| At least 30 min of physical activity | ||||||
| Adherent | 54 (26.3) | |||||
| Non-adherent | 151 (73.7) | |||||
| Specific exercise session | ||||||
| Adherent | 34 (16.5) | |||||
| Non-adherent | 172 (83.5) | |||||
| Self-monitoring of blood glucose | ||||||
| Adherent | 108 (52.4) | |||||
| Non-adherent | 98 (47.6) | |||||
| Foot care | ||||||
| Adherent | 109 (52.9) | |||||
| Non-adherent | 96 (46.6) | |||||
| Smoking | 33 (16.0) | |||||
| Number of cigarettes per day (mean ± SD) | 17.2 ± 13.0 | |||||
| Sedentary hours per day (mean ± SD) | 7.8 ± 4.6 | |||||
| Sleep duration at night | ||||||
| >8 h | 26 (12.6) | |||||
| 6–8 h | 107 (51.9) | |||||
| <6 h | 73 (35.4) | |||||
| Sleep duration at night | ||||||
| >8 h | 29 (14.1) | |||||
| 6–8 h | 92 (44.9) | |||||
| <6 h | 84 (41.0) | |||||
Changes in frequency of performing self-care activities during the COVID-19 pandemic compared to a similar pre-pandemic time.
| Self-care activity | Changes in frequency of engaging in self-care activities n (%) | ||||
|---|---|---|---|---|---|
| Increased significantly | Increased | Stayed the same | Decreased | Decreased Significantly | |
| Healthful eating habits | 13 (6.3) | 19 (9.3) | 148 (72.2) | 18 (8.8) | 7 (3.4) |
| Exercise | 9 (4.4) | 13 (6.3) | 108 (52.4) | 31 (15.0) | 45 (21.8) |
| Self-monitoring of blood glucose | 21 (10.3) | 13 (6.4) | 143 (70.1) | 17 (8.3) | 10 (4.9) |
| Foot care | 9 (4.4) | 6 (2.9) | 187 (91.2) | 3 (1.5) | 0 (0.0) |
| Smoking | 3 (9.1) | 3 (9.1) | 19 (57.6) | 4 (12.1) | 4 (12.1) |
Responses of the 33 participants who reported smoking.
Challenges of people with type 2 diabetes in accessing and using diabetes care during the COVID-19 pandemic (N = 206).
| Level of difficulty n (%) | |||
|---|---|---|---|
| Statements describing access and use of diabetes care | Challenging | Somewhat challenging | Not challenging |
| Having regular appointments with the diabetes doctor | 36 (17.6) | 26 (12.7) | 143 (69.8) |
| Receiving a lot of information about COVID-19 from many sources | 29 (14.4) | 30 (14.9) | 142 (70.6) |
| Communicating concerns about diabetes management with the health care team (doctor, nurse, dietitian, or diabetes educator) | 22 (10.8) | 19 (9.3) | 163 (79.9) |
| Doing regular lab tests | 16 (7.8) | 20 (9.8) | 168 (82.4) |
| Obtaining diabetes medicines from the pharmacy | 9 (4.4) | 12 (5.9) | 183 (89.7) |
| Receiving counseling from the pharmacists about the use of prescribed diabetes treatment | 10 (4.9) | 10 (4.9) | 184 (90.2) |
| Getting a prescription from the doctor | 9 (4.4) | 10 (4.9) | 186 (90.7) |
| Obtaining diabetes medical supplies (e.g., insulin syringes or pens, test strips, etc.) | 7 (3.4) | 10 (4.9) | 187 (91.7) |
| Paying for diabetes medicine | 13 (6.4) | 2 (1.0) | 188 (92.6) |
| Using prescribed diabetes medicine as prescribed by the doctor | 3 (1.5) | 3 (1.5) | 198 (97.1) |
Change in clinical parameters and diabetes treatment of people with type 2 diabetes during COVID-19 pandemic (N = 206).
| Clinical parameters | Mean ± SD | ||
|---|---|---|---|
| Before COVID-19 | During COVID-19 | ||
| HbA1c (%) | 8.2 ± 1.9 | 8.0 ± 1.7 | 0.080 |
| LDL (mg/dL) | 76.7 ± 31.1 | 74.7 ± 30.0 | 0.264 |
| Total cholesterol (mg/dL) | 151.3 ± 37.4 | 149.4 ± 37.4 | 0.830 |
| Serum creatinine (mg/dL) | 0.9 ± 1.0 | 0.9 ± 1.1 | 0.996 |
| Urinary albumin (mg) | 62.8 ± 146.1 | 73.4 ± 173.7 | 0.077 |
| BMI (kg/m2) | 31.1 ± 5.9 | 31.0 ± 6.0 | 0.609 |
| n (%) | |||
| Combination of OHA/insulin/GLP-1 receptor agonist | 97 (47.1) | ||
| OHA only | 83 (40.3) | ||
| Insulin only | 16 (7.8) | ||
| GLP-1 receptor agonist only | 3 (1.5) | ||
| Diet alone | 1 (0.5) | ||
| n (%) | |||
| No modifications | 150 (72.8) | ||
| Treatment modified | 51 (25.0) | ||
| Treatment intensified | 44 (86.3) | ||
| Treatment de-intensified | 6 (11.8) | ||
| Types of treatment modification | |||
| Insulin added/switched to insulin | 7 (13.7) | ||
| Insulin regimen intensified | 28 (54.9) | ||
| Insulin regimen de-intensified/discontinued | 4 (7.8) | ||
| OHA added | 7 (13.7) | ||
| OHA dose decreased/OHA discontinued | 4 (7.8) | ||
| GLP-1 receptor agonist added | 2 (3.9) | ||
*LDL: Low density lipoprotein cholesterol; BMI: Body mass index; OHA: Oral hypoglycemic agent(s); GLP-1: glucagon-like peptide-1.
Associations between challenges with and knowledge about diabetes management with changes in self-care activities during the COVID-19 pandemic.
| Changes in frequency of engaging in self-care activities n (%) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthy eating habits | Exercise | SMBG | Foot care | Smoking | |||||||||||||||||
| Decreased | Same | Increased | Decreased | Same | Increased | Decreased | Same | Increased | Decreased | Same | Increased | Decreased | Same | Increased | |||||||
| Number of challenges | <2 | 10 (7.5) | 101 (75.4) | 23 (17.2) | 38 (28.1) | 82 (60.7) | 15 (11.1) | 19 (14.3) | 96 (72.2) | 18 (13.5) | .579 | 1 (0.7) | 127 (94.8) | 6 (4.5) | .078 | 5 (22.7) | 14 (63.6) | 3 (13.6) | .504 | ||
| ≥ 2 | 13 (20.6) | 41 (65.1) | 9 (14.3) | 33 (52.4) | 24 (38.1) | 6 (9.5) | 7 (11.1) | 44 (69.8) | 12 (19.0) | 2 (3.2) | 54 (85.7) | 7 (11.1) | 2 (20.0) | 5 (50.0) | 3 (30.0) | ||||||
| Items on knowledge about diabetes management rated ‘insufficient’ | <2 | 15 (9.0) | 125 (75.3) | 26 (15.7) | .057 | 56 (33.5) | 92 (55.10 | 19 (11.4) | .091 | 16 (9.6) | 119 (71.7) | 31 (18.7) | 2 (1.2) | 151 (90.4) | 14 (8.4) | .295 | 7 (25.0) | 19 (67.9) | 2 (7.1) | ||
| ≥ 2 | 9 (23.7) | 24 (63.2) | 5 (13.2) | 20 (52.6) | 16 (42.1) | 2 (5.3) | 11 (28.9) | 24 (63.2) | 3 (7.9) | 1 (2.6) | 36 (94.7) | 1 (2.6) | 1 (20.0) | 0 (0.0) | 4 (80.0) | ||||||